RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

Inclusion Criteria

• •Histologically or cytologically confirmed diagnosis of an advanced, malignant, solid tumor(s) with all standard treatment options having been exhausted or declined.
• •Eastern Cooperative Group (ECOG) performance status is 0-2 at Screening.
• •Measurable disease per RECIST v1.1 by radiographic techniques
• •Acceptable liver function, serum creatinine and hematological status
• •Female subjects of childbearing potential, and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of RRx-001.
• •Subjects with brain metastases are eligible